Exposure of human subcutaneous adipose tissue and skeletal muscle tissue to unbound active drug after inhalation of high-dose ciclesonide or budesonide Source: Eur Respir J 2007; 30: Suppl. 51, 351s Year: 2007
Deposition and metabolism of inhaled ciclesonide in the human lung Source: Eur Respir J 2010; 36: 1113-1119 Year: 2010
Different tissue accumulation kinetics of ciclesonide-active metabolite and budesonide in mice Source: Eur Respir J 2006; 28: Suppl. 50, 433s Year: 2006
Tissue accumulation kinetics of ciclesonide-active metabolite and budesonide in mice Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Concentrations of ciclesonide and its metabolites in the human lung after inhalation of 1280 μg ciclesonide Source: Eur Respir J 2006; 28: Suppl. 50, 212s Year: 2006
Highly lipophilic fatty acid esters of the active metabolite of ciclesonide formed in vitro in rat lung tissue Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004
Pronounced tissue and plasma protein binding of ciclesonide is responsible for reduced pharmacodynamic potency in the lung Source: Eur Respir J 2007; 30: Suppl. 51, 351s Year: 2007
Tissue retention and esterification is greater for budesonide than for ciclesonide in trachea ex vivo Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004
Greater esterification and retention of budesonide in the airways and lung as compared to ciclesonide after repeated intratracheal administration in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004
Determination of tissue concentrations of metabolites in surgical preparations following inhalation of beclomethasone-dipropionate using conventional and extrafine aerosols Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003
Esterification prolongs retention of budesonide but not ciclesonide - active principle in rat trachea Source: Eur Respir J 2005; 26: Suppl. 49, 369s Year: 2005
Glycosaminoglycan synthesis is modulated by ciclesonide in human lung cells Source: Eur Respir J 2004; 24: Suppl. 48, 346s Year: 2004
Efficient deposition and absorption of orally inhaled indacaterol in the lungs Source: Annual Congress 2011 - COPD management Year: 2011
Esterases involved in the hydrolysis of ciclesonide in human tissues Source: Eur Respir J 2003; 22: Suppl. 45, 267s Year: 2003
Relationship between the inhaled and pulmonary absorbed dose of budesonide and mometasone furoate: A study in the isolated perfused rat lung Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Urinary pharmacokinetic method to identify the relative bioavailability of beclometasone dipropionate (BDP) to the lung and body following inhalation Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
TGFβ-induced proteoglycan production and α-smooth muscle actin expression in cultured human lung fibroblasts is inhibited by combination of budesonide and formoterol Source: Eur Respir J 2004; 24: Suppl. 48, 251s Year: 2004
Uptake, retention and metabolism of ciclesonide in human alveolar epithelial cells Source: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005
A novel tool for the assessment of pulmonary disposition of dry powder aerosols; the isolated and perfused rat lung exposed to budesonide, formoterol and terbutaline Source: Eur Respir J 2007; 30: Suppl. 51, 352s Year: 2007
Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002